Lactobacillus casei: Difference between revisions
Jump to navigation
Jump to search
imported>Kelvin Chan |
imported>Kelvin Chan |
||
Line 1: | Line 1: | ||
==Current Research== | ==Current Research== | ||
L. casei is attributed to the modulation of the host's immune response. According to Yakult Central Institute for Microbiological Research in Tokyo, "Lactobacillus casei strain Shirota (LcS) has been shown to have potent anti-tumour and anti-metastatic effects on transplantable tumour cells and to suppress chemically-induced carcinogenesis in rodents." Their findings suggest that treatment with LcS has the potential to improve or prevent diseases by increasing the innate and acquired immune response. | L. casei is attributed to the modulation of the host's immune response. According to Yakult Central Institute for Microbiological Research in Tokyo, "Lactobacillus casei strain Shirota (LcS) has been shown to have potent anti-tumour and anti-metastatic effects on transplantable tumour cells and to suppress chemically-induced carcinogenesis in rodents." Their findings suggest that treatment with LcS has the potential to improve or prevent diseases by increasing the innate and acquired immune response. | ||
Revision as of 16:05, 4 April 2009
Current Research
L. casei is attributed to the modulation of the host's immune response. According to Yakult Central Institute for Microbiological Research in Tokyo, "Lactobacillus casei strain Shirota (LcS) has been shown to have potent anti-tumour and anti-metastatic effects on transplantable tumour cells and to suppress chemically-induced carcinogenesis in rodents." Their findings suggest that treatment with LcS has the potential to improve or prevent diseases by increasing the innate and acquired immune response.